Why are new drugs so expensive?
© 2018 médecine/sciences – Inserm..
Putting an end to an innovation crisis, the reality of which is the subject of debate, recent pharmaceutical innovations, the result of a combination of scientific, industrial, financial, political and economic reasons, lead to a diversification of products and to a strong interest of pharmaceutical companies for the so-called "niche" products (targeted therapies, rare diseases, etc.). These new molecules are put on the market at much higher prices than in the past. In the absence of reliable information on the costs borne by manufacturers, and knowing that high levels of margins have been observed, these prices raise legitimate questions. These are also motivated by the lack of relationship between the price and the therapeutic benefit of these new molecules. In France, faced with levels of expenditure likely to weaken the financial sustainability of the social protection system, the public authorities have so far always favored interventions on prices or the conditions and volume of reimbursement, in accordance with the existing regulation. Other regulations (use of the statutory license, group purchase, etc.) could in the future be used in a growing concern for the efficiency of public expenditure. The difficulties encountered in regulating a deeply transformed industrial sector call for a reform of national evaluation and regulation systems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Medecine sciences : M/S - 34(2018), 4 vom: 10. Apr., Seite 354-361 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Pourquoi les nouveaux médicaments sont-ils si chers ? |
|---|
| Beteiligte Personen: |
Le Galès, Catherine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.09.2018 Date Revised 27.09.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1051/medsci/20183404017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283068698 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283068698 | ||
| 003 | DE-627 | ||
| 005 | 20231225035533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1051/medsci/20183404017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0943.xml |
| 035 | |a (DE-627)NLM283068698 | ||
| 035 | |a (NLM)29658480 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Le Galès, Catherine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Why are new drugs so expensive? |
| 246 | 3 | 3 | |a Pourquoi les nouveaux médicaments sont-ils si chers ? |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2018 | ||
| 500 | |a Date Revised 27.09.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 médecine/sciences – Inserm. | ||
| 520 | |a Putting an end to an innovation crisis, the reality of which is the subject of debate, recent pharmaceutical innovations, the result of a combination of scientific, industrial, financial, political and economic reasons, lead to a diversification of products and to a strong interest of pharmaceutical companies for the so-called "niche" products (targeted therapies, rare diseases, etc.). These new molecules are put on the market at much higher prices than in the past. In the absence of reliable information on the costs borne by manufacturers, and knowing that high levels of margins have been observed, these prices raise legitimate questions. These are also motivated by the lack of relationship between the price and the therapeutic benefit of these new molecules. In France, faced with levels of expenditure likely to weaken the financial sustainability of the social protection system, the public authorities have so far always favored interventions on prices or the conditions and volume of reimbursement, in accordance with the existing regulation. Other regulations (use of the statutory license, group purchase, etc.) could in the future be used in a growing concern for the efficiency of public expenditure. The difficulties encountered in regulating a deeply transformed industrial sector call for a reform of national evaluation and regulation systems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Drugs, Investigational |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Medecine sciences : M/S |d 1996 |g 34(2018), 4 vom: 10. Apr., Seite 354-361 |w (DE-627)NLM08683102X |x 1958-5381 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2018 |g number:4 |g day:10 |g month:04 |g pages:354-361 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1051/medsci/20183404017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2018 |e 4 |b 10 |c 04 |h 354-361 | ||